nach oben

Erschienen in:

12.02.2022 | Research Letter

Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer

verfasst von: Mohamed A. Gouda, Emily Ong, Helen J. Huang, Laron W. McPhaul, Steve Yoon, Filip Janku, Andrew G. Gianoukakis

Erschienen in: Endocrine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Excerpt

There has been a growing interest in characterizing molecular alterations that can drive oncogenesis in thyroid cancer [1]. These molecular alterations are increasingly gaining importance in diagnosis and prognostication and can represent targets for therapeutic intervention. Some of the most studied actionable mutations are BRAF alterations, which are present in 30–70% of patients [2‐4]. These alterations lead to unbridled activation of the MAPK pathway which controls cell growth and division, thus contributing to thyroid cancer pathogenesis [1, 3, 5‐9]. …

Nur mit Berechtigung zugänglich

M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184–199 (2013)CrossRef

A. Zaman, W. Wu, T.G. Bivona, Bivona, Targeting oncogenic BRAF: past, present, and future. Cancers 11, 1197 (2019).CrossRef

M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309, 1493–1501 (2013)CrossRef

A. Czarniecka, M. Oczko-Wojciechowska, M. Barczynski, BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 5, 495–505 (2016)CrossRef

L.R.Q. Barreno, J.B.H. Mello, M.C. Barros-Filho, A.L. Francisco, T.C. Chulam et al. Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma. Braz. J. Otorhinolaryngol. (2020). https://www.sciencedirect.com/science/article/pii/S1808869420301373?via%3Dihub. Online ahead of print

M.J. Garnett, R. Marais, Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313–319 (2004)CrossRef

P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004)CrossRef

E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457 (2003)PubMed

J. Ge, J. Wang, H. Wang, X. Jiang, Q. Liao et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J. Cancer 11, 932–939 (2020)CrossRef

10.

M. Gerlinger, A.J. Rowan, S. Horswell, M. Math, J. Larkin et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012)CrossRef

11.

C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014)CrossRef

12.

C. Rolfo, P.C. Mack, G.V. Scagliotti, P. Baas, F. Barlesi et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13, 1248–1268 (2018)CrossRef

13.

M. Daniotti, V. Vallacchi, L. Rivoltini, R. Patuzzo, M. Santinami et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J. Cancer 120, 2439–2444 (2007)CrossRef

14.

K.W. Cradic, D. Milosevic, A.M. Rosenberg, L.A. Erickson, B. McIver et al. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J. Clin. Endocrinol. Metab. 94, 5001–5009 (2009)CrossRef

15.

J.Y. Kwak, J.J. Jeong, S.W. Kang, S. Park, J.R. Choi et al. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas. Head. Neck 35, 1630–1633 (2013)CrossRef

16.

V. Condello, E. Macerola, C. Ugolini, L. De Napoli, C. Romei et al. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head. Neck 40, 1752–1758 (2018)PubMed

17.

B.H. Kim, I.J. Kim, B.J. Lee, J.C. Lee, I.S. Kim et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med. J. 56, 634–640 (2015)CrossRef

18.

J.M. Fussey, J.L. Bryant, N. Batis, R.J. Spruce, A. Hartley et al. The clinical utility of cell-free DNA measurement in differentiated thyroid cancer: a systematic review. Front Oncol. 8, 132 (2018)CrossRef

19.

D.M. Allin, R. Shaikh, P. Carter, K. Thway, M.T.A. Sharabiani et al. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur. J. Cancer 103, 165–175 (2018)CrossRef

20.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef

21.

C.P. Gilfillan, Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J. Surg. 80, 33–40 (2010)CrossRef

Titel: Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer
verfasst von: Mohamed A. Gouda
Emily Ong
Helen J. Huang
Laron W. McPhaul
Steve Yoon
Filip Janku
Andrew G. Gianoukakis
Publikationsdatum: 12.02.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03004-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis

Impact of transforming growth factor beta 1 on normal and thyroid cancer side population cells

An alternative way to define hemodynamic instability in the pheochromocytoma surgery

Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study

Diagnostic efficacy, performance and safety of side-cut core needle biopsy for thyroid nodules: comparison of automated and semi-automated biopsy needles

The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin